SALIVARY STIMULATION: NEWER TECHNIQUES

Aatika Islam¹, Shalabh Kumar², A.P.Nirmal Raj³, Roopal Dubey⁴, Dhiren Sanjeev Shah⁵, Tambolkar Rajeshwari A⁶ Post Graduate^{1,4,5,6} Professor² Professor² & Head³

1-6- Department of Prosthodontics and crown & bridge, Teerthanker Mahaveer Dental college and Research Centre, Moradabad, Uttar Pradesh, India

Abstract

Saliva play very important role in maintaining health. It has several functions, such as detritus dilution, lubrication of oral cavity, bolus, maintaining the oral mucosa integrity, food solubilization, mechanical cleansing action, and remineralization. Decrease in flow of saliva is hyposalivation which may be caused due to certain autoimmune diseases, connective tissue complications, as a result of radiation therapy to neck and head, certain medications, or due to some other condition. Oral dryness is a symptom of xerostomia. Treating xerostomia is very challenging in dental practice. Recently, TENS used to increase saliva production in patients with radiation therapy and even in healthy patients. There are intraoral devices or the three generation which play a key role in increasing salivary secretions. This article presents a review about new developments for the treatment of xerostomia by incorporating salivary pacemakers and its three generations.

Keywords: xerostomia, auriculotemporal nerve, neuro-electrostimulator, osteointegrated implant.

INTRODUCTION:

It can be said that saliva lacks the emotional aspects of tears, the sincerity of sweat, and the drama of blood, which is why saliva is not one of popular bodily fluids, (Mandel 1990). Although, saliva is not required for any life-sustaining functions, and is taken for granted, but its absence or diminution can lead to significant reduction in the perceptions of quality of life for a patient and may significantly increase morbidity^{1,2}. Primarily, saliva constitutes of proteins, water, and electrolytes³, these components augments and facilitates speech, lubrication, irrigation, taste, swallowing, and mucous membranes' protection in the upper digestive tract¹. Moreover, saliva prevents the dental caries of teeth with its antimicrobial and buffering activities of physiological functions³.

One of the symptoms of oral dryness is Xerostomia, which means that the fluid loss from the oral cavity is more than the salivary flow, which is majorly a result of loss of salivary gland hypofunction⁴. Xerostomia is a common problem, where women are 10-29% more likely to be affected as compared to men⁵ in middle to late life which suggests the anticholinergic action of several drugs, and this condition can be found in young adults also, but rarely in children.^{6,7}

Dentists face many problems while treating dry mouth patients, where treatment with salivary substitutes, lubricants, adoption of masticatory methods or salivary stimulation by gustatory can help but not for long period of time. Xerostomia reccurs once the treatment is interrupted8. In a recent study functional nonpharmacological method were used in treating xerostomia; however, none of the treatments present currently can fulfill these expectations⁹.

Therefore, this report presents the advances of neuroelectro-stimulation in xerostomia patients.

ETIOLOGY:

Several complications of connective tissues, autoimmune diseases, use of medications, radiation therapies to neck and head are a leading cause to xerostomia.

Hyposalivation leads to several health problems which can seriously affect the nutritional status, taste, dietary habits, speech, quality of life, and tolerance to dental prosthesis for a patient, which can further increase the risk of periodontal diseases, susceptibility to dental caries, oral infection including candidiasis, and tooth loss¹⁰

Drugs Associated With Xerostomia¹

Category	Generic Name	
Autichedinergic agenta	Atropine Belladonna Benztopine Oxytnatymn Scopolamine Tribexyphendyl	
Antidepressant and antipsychotic agents Selective serutorin-respeake inhubitors	Citalopram Fluoretine Paroxetine Sertraline Venlafiwine	
Tricyclic antidepressants	Amitriptyline Designamine	
Heterocyclic antidepressants	Imigramine Haloperidol Mirtazapine	
Monoamine oxidase inhibitors Atypical antidepressants	Pamoride Phenelizine Bupropion Nefaxodone Olanzapine	
Diuretic agents	Chlorothazide Fucoamide Hydrochlorothazide Taamterene	

Sedative and anniolytic agents	Alprazolam
	Diazepam
	Flurnzepam
	Temazepam
	Triazolam
Antihypertensity agents	Captopeil
	Clonidine
	Emalaperil
	Ouanfacine
	Lisinopril
	Methyldopa
	terrary weight
Moacle relaxant agenta	Cyclobenzaprine
	Orphenadrine
	Tiganidine
	s an an or a second sec
Analgesic agents	Codeine
Central nervous system/opioids	Meperidine
	Methadone
	Pentazocine
	Proposyphene
	Tramadol
Non-steroidal anti-inflammatory agents	Diffumisal
	Ibuprofen
	Naproxen
	Piroxicam
Antihistamines	Astenizole
- second s	Brompheniumine
	Chlorpbeniramine
	Diphenhydramine
	Loratadine

Salivary Glands

20% of the total saliva is secreted by parotid gland, which is serous type histologically. 70% of the total saliva is secreted by submandibular gland which is mixed type both serous and mucous. 5% of the total saliva secreted sublingual salivary gland which is also mixed type. In salivary glands Acinar cells discharge secretory granules containing salivary enzymes to the ducts. Almost 1500 mL of saliva is produce per day¹¹.

Management / Treatment

Extraoral	
•Tens therapy	
Intraoral	
•Three Generations Of Pacemakers	


Transcutaneous Electric Nerve Stimulation

It was reported that when the TENS is placed over the major salivary gland i.e. parotid gland, it tends to increase the saliva production which is caused by radiation specially in healthy individuals and patients with xerostomia, auriculotemporal nerve (efferent pathway) might be stimulated by TENS which supplies the secretomotor drive to the parotid gland. 12,13 TENS was classified as class II device by the FDA in 1972^{14} .

Salivary Pacemakers (Intraoral devices)


First-generation electrostimulating devices

USA (Salitron; Biosonics, Fort Washington, PA, USA) in 1988 approved a device for neuro-electrostimulation to increase salivary secretion. To generate salivation and to provide signals to related neuron probe was used each day for a few minutes between the palate and dorsum of the tongue (Figure 1)^{15,16,17}. But because of its high price and large size its wider use was hampered.



Second-generation devices

(GenNarino Saliwell Ltd. Germany) Removable intraoral appliance the second-generation salivary neuro electrostimulator customized by making impression of their arches and fits on the mandibular arch like mouthguard. Its convenient for the patient to insert and remove. In order to allow safe and contamination-free intraoral application the electronic components are fixed within the appliance. It helps the patients to communicate with the device and also the function can be modified as its a remote control [Figure 2]. The dryness of the mouth can be reduced during the application and also 10 mins after its removed by using this device.



Dental implant-based third-generation intraoral device

Miniature neuroelectrostimulating device was developed by the Saliwell Crown Saliwell Ltd. Germany. Components of second-generation were miniaturized and packaged into a device which is permanently mounted on a commercially available osteointegrated implant, which is of same shape and dimensions of a molar tooth. The device also have wetness sensor which detect changes in wetness/dryness. They are implanted in lower third molar region to avoid interference with normal oral function and also the close proximity to the lingual nerve which carries both afferent and efferent salivary impulses⁹. [Figure 3].



(f) Radiograph of both the implant and crown

CONCLUSION

Condition of hyposalivation and xerostomia interferes with nutrition, leads to decline of oral hygiene. This article highlights the role a prosthodontist plays by presenting new developments for treatment of xerostomia by in corporating salivary pace makers and its three generations that play a key role in increasing salivary flow. It is a prime concern to prevent and treat xerostomia which is a common clinical challenge in oral medicine practice.

REFERENCES

1.Guggenheimer J, Moore PA. Xerostomia: Etiology, recognition and treatment. J Am Dent Assoc. 2003;134:61.

2. Sreebny LM, Valdini A. Xerostomia. A neglected symptom. Arch Intern Med. 1987;147:1333–7.

3. International Dental Federation. Saliva: Its role in health and disease. Working Group 10 of the

Commission on Oral Health, Research and Epidemiology (CORE) Int Dent J. 1992;42(Supp 12):287–304

4. Fox PC, van der Ven PF, Sonies BC, Weiffenbach JM, Baum BJ. Xerostomia: Evaluation of symptom with increasing significance. J Am Dent Assoc. 1985;110:519–25.

5. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:28–46.

6. Billings RJ, Proskin HM, Moss ME. Xerostomia and associated factors in a community-dwelling adult population. Community Dent Oral Epidemiol. 1996;24:312–6.

7. Schein OD, Hochberg MC, Muñoz B, Tielsch JM, Bandeen- Roche K, Provost T, et al. Dry eye and dry mouth in the elderly: A population-based assessment. Arch Intern Med. 1999;159:1359–63.

8. Greenspan D. Xerostomia: Diagnosis and management. Oncology (Williston Park) 1996;10:7–11.

9. Lafaurie G, Fedele S, Lopez RM, Wolff A, Strietzel F, Porter SR, et al. Biotechnological advances in neuroelectro-stimulation for the treatment of hyposalivation and xerostomia. Med Oral Pathol Oral Cir Bucal. 2009;14:E76–80.

10. Atkinson JC, Wu AJ. Salivary gland dysfunction: Causes, symptoms, treatment. J Am Dent Assoc. 1994;125:409–16.

11. Ganong WF. Regulation of gastrointestinal function. In: Ganong WF, editor. Review of Medical Physiology. 7th ed. Connecticut: Appleton and Lange; 1995. pp. 260– 72.

12. Wong RK, Jones GW, Sagar SM, Babjak AF, Whelan T. A phase I-II study in the use of acupuncturelike transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:472–80.

13. Hargitai IA, Sherman RG, Strother JM. The effects of electrostimulation on parotid saliva flow: A pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:316–20.

14. Kasat V, Gupta A, Ladda R, Kathariya M, Saluja H, Farooqui AA. Transcutaneous electric nerve stimulation (TENS) in dentistry- A review. J Clin Exp Dent. 2014;6(5):e562-568.

15. Steller M, Chou L, Daniels TE. Electrical stimulation of salivary flow on patients with Sjögren's syndrome. J Dent Res. 1988;67:1334–7.

16. Talal N, Quinn JH, Daniels TE. The clinical effects of electrostimulation on salivary function of Sjögren's syndrome patients. A placebo controlled study. Rheumatol Int. 1992;12:43–5.

17. Weiss WW, Jr, Brenman HS, Katz P, Bennett JA. Use of an electronic stimulator for the treatment of dry mouth. J Oral Maxillofac Surg. 1986;44:845–50.

CORRESPONDING AUTHOR

Dr. Aatika Islam, Post Graduate, Department of Prosthodontics and crown & bridge, Teerthanker Mahaveer Dental College and Research Centre, Moradabad, Uttar Pradesh, India Email Id: aatikaislam1october@gmail.com Contact No. +919639657375

How to cite this article: Islam A, Kumar S, Raj N A P, Dubey R ,Shah D, Rajeshwari T. Salivary stimulation: Newer techniques. TMU J Dent 2021;8(2)16-19